Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alexion’s Soliris Blood Treatment Will Cost Almost $400,000 Per Year

Executive Summary

Alexion Pharmaceuticals is launching its paroxysmal nocturnal hemoglubinuria Soliris (eculizumab) with a treatment support service with case managers to help facilitate reimbursement

You may also be interested in...

Priority Review Voucher Not For Sale, Alexion Says After Strensiq Approval

Alexion plans to use voucher for one of its own products and might be targeting its next-generation version of blockbuster Soliris.

Reimbursing Rare Disease Drugs: Getting Away From High Co-Pays

Former CMS Administrator Mark McClellan argues that drugs for rare disease should not be on the high-cost-sharing specialty tier of Medicare Part D formularies. “High value” therapies deserve low co-pays, he argues.

Collaboration Needed To Ensure Access To Orphan Drugs – Express Scripts Exec

In an effort to ensure that there is access to high-priced drugs that treat rare diseases, relevant stakeholders, including manufacturers, payers, patients and physicians, need to come together and collaborate on access solutions that meet the needs of all parties, Express Scripts VP of Pharma Strategies and Account Management Bill Martin tells NORD/DIA conference.

Related Content

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts